PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients; and Emflaza (deflazacort) for treating Duchenne muscular dystrophy. It is developing Translarna, which is in Phase II clinical study for the treatment of nonsense mutation aniridia and nonsense mutation Dravet syndrome/CDKL5; and RG7916 for the treatment of patients with spinal muscular atrophy, as well as PTC596, an orally bioavailable and potent small molecule that has completed Phase I study, which targets solid tumor cell populations by reducing the activity and amount of BMI1. The company has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., and the Spinal Muscular Atrophy Foundation to develop and commercialize compounds identified under its spinal muscular atrophy sponsored research program; research collaboration with Massachusetts General Hospital for the treatment of rare genetic disorders resulting from pre-mRNA; and research collaboration with CHDI Foundation, Inc. to discover and develop small-molecule therapeutics for Huntington's disease. PTC Therapeutics, Inc. was founded in 1998 and is headquartered in South Plainfield, New Jersey.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone908-222-7000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$264.73 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/8/2019 (Estimated)
OptionableOptionable
PTC Therapeutics (NASDAQ:PTCT) Frequently Asked Questions
What is PTC Therapeutics' stock symbol?
PTC Therapeutics trades on the NASDAQ under the ticker symbol "PTCT."
How were PTC Therapeutics' earnings last quarter?
PTC Therapeutics, Inc. (NASDAQ:PTCT) released its earnings results on Monday, November, 5th. The biopharmaceutical company reported ($1.06) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.40) by $0.66. The biopharmaceutical company earned $53.59 million during the quarter, compared to analyst estimates of $70.56 million. PTC Therapeutics had a negative return on equity of 31.63% and a negative net margin of 48.38%. The firm's revenue was up 28.0% on a year-over-year basis. During the same quarter last year, the business posted ($0.82) EPS. View PTC Therapeutics' Earnings History.
When is PTC Therapeutics' next earnings date?
What price target have analysts set for PTCT?
8 brokers have issued 1 year price objectives for PTC Therapeutics' stock. Their predictions range from $31.00 to $61.00. On average, they expect PTC Therapeutics' stock price to reach $47.1429 in the next twelve months. This suggests a possible upside of 26.0% from the stock's current price. View Analyst Price Targets for PTC Therapeutics.
What is the consensus analysts' recommendation for PTC Therapeutics?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PTC Therapeutics in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for PTC Therapeutics.
What are Wall Street analysts saying about PTC Therapeutics stock?
Here are some recent quotes from research analysts about PTC Therapeutics stock:
- 1. According to Zacks Investment Research, "PTC Therapeutics, Inc. is a biopharmaceutical company. It is focused on the discovery and development of orally administered, small-molecule drugs for genetic disorders, oncology and infectious disease. PTC Therapeutics, Inc. is based in South Plainfield, United States. " (3/5/2019)
- 2. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and $61 Price Target and think that risk/reward is positive for PTC heading into updates on SMA and AADC. After today’s update, we remain confident in both the regulatory and commercial pathway for risdiplam and view it as a largely underappreciated opportunity for PTC. The company is eligible to receive $15M in milestone payments each for NDA and MAA filings and $20M each for first US and EU sale. We model $3B 2025 WW sales for risdiplam and $360M 2025 royalties to PTC on an unadjusted basis. We expect further updates on these data at AAN (May 4-10)." (2/28/2019)
- 3. William Blair analysts commented, "We show reported earnings, our estimates, and consensus in exhibit 1." (11/6/2018)
Has PTC Therapeutics been receiving favorable news coverage?
News articles about PTCT stock have been trending neutral this week, according to InfoTrie. The research group identifies negative and positive media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. PTC Therapeutics earned a news impact score of 0.4 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 6.0 out of 10, meaning that recent media coverage is somewhat likely to have an effect on the company's share price in the next several days.
Who are some of PTC Therapeutics' key competitors?
Some companies that are related to PTC Therapeutics include Bausch Health Companies (BHC), Beigene (BGNE), Jazz Pharmaceuticals (JAZZ), SAGE Therapeutics (SAGE), Loxo Oncology (LOXO), Marina Biotech (MRNA), Perrigo (PRGO), Dr.Reddy's Laboratories (RDY), Amarin (AMRN), Catalent (CTLT), Nektar Therapeutics (NKTR), Alkermes (ALKS), Ascendis Pharma A/S (ASND), Array Biopharma (ARRY) and United Therapeutics (UTHR).
What other stocks do shareholders of PTC Therapeutics own?
Who are PTC Therapeutics' key executives?
PTC Therapeutics' management team includes the folowing people:
- Dr. Stuart W. Peltz, Co-Founder, CEO & Exec. Director (Age 58)
- Dr. Allan Steven Jacobson, Co-Founder, Chairman of Scientific Advisory Board & Director (Age 72)
- Ms. Christine Utter, Principal Financial Officer & Treasurer (Age 40)
- Mr. Marcio Souza, Chief Operating Officer (Age 39)
- Dr. Neil Almstead, Exec. VP of Research, Pharmaceutical Operations & Technology (Age 51)
Who are PTC Therapeutics' major shareholders?
PTC Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.47%), RTW Investments LP (3.35%), Orbimed Advisors LLC (2.65%), Great Point Partners LLC (2.14%), D. E. Shaw & Co. Inc. (1.74%) and Northern Trust Corp (1.03%). Company insiders that own PTC Therapeutics stock include Christine Marie Utter, Dawn Svoronos, Marcio Souza, Michael Schmertzler, Neil Gregory Almstead and Stuart Walter Peltz. View Institutional Ownership Trends for PTC Therapeutics.
Which institutional investors are selling PTC Therapeutics stock?
PTCT stock was sold by a variety of institutional investors in the last quarter, including RTW Investments LP, D. E. Shaw & Co. Inc., Frontier Capital Management Co. LLC, venBio Select Advisor LLC, Millennium Management LLC, Northern Trust Corp, Two Sigma Advisers LP and Castleark Management LLC. Company insiders that have sold PTC Therapeutics company stock in the last year include Christine Marie Utter, Marcio Souza, Neil Gregory Almstead and Stuart Walter Peltz. View Insider Buying and Selling for PTC Therapeutics.
Which institutional investors are buying PTC Therapeutics stock?
PTCT stock was purchased by a variety of institutional investors in the last quarter, including Great Point Partners LLC, Orbimed Advisors LLC, Sphera Funds Management LTD., Elk Creek Partners LLC, Candriam Luxembourg S.C.A., BlackRock Inc., Bank of New York Mellon Corp and Bank of Montreal Can. Company insiders that have bought PTC Therapeutics stock in the last two years include Dawn Svoronos and Michael Schmertzler. View Insider Buying and Selling for PTC Therapeutics.
How do I buy shares of PTC Therapeutics?
Shares of PTCT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is PTC Therapeutics' stock price today?
One share of PTCT stock can currently be purchased for approximately $37.41.
How big of a company is PTC Therapeutics?
PTC Therapeutics has a market capitalization of $2.18 billion and generates $264.73 million in revenue each year. The biopharmaceutical company earns $-128,080,000.00 in net income (profit) each year or ($1.84) on an earnings per share basis.
What is PTC Therapeutics' official website?
How can I contact PTC Therapeutics?
PTC Therapeutics' mailing address is 100 CORPORATE COURT, SOUTH PLAINFIELD NJ, 07080. The biopharmaceutical company can be reached via phone at 908-222-7000 or via email at [email protected]
MarketBeat Community Rating for PTC Therapeutics (NASDAQ PTCT)
MarketBeat's community ratings are surveys of what our community members think about PTC Therapeutics and other stocks. Vote "Outperform" if you believe PTCT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTCT will underperform the S&P 500 over the long term. You may vote once every thirty days.
